Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $400.00 at HC Wainwright

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price increased by research analysts at HC Wainwright from $395.00 to $400.00 in a research note issued on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 162.66% from the company’s current price.

A number of other brokerages have also issued reports on ALNY. Needham & Company LLC reiterated a “buy” rating and set a $200.00 price target on shares of Alnylam Pharmaceuticals in a research note on Thursday, May 2nd. Citigroup dropped their price target on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating on the stock in a research note on Friday, February 16th. Morgan Stanley dropped their price target on shares of Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 13th. Wolfe Research started coverage on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 15th. They set a “peer perform” rating on the stock. Finally, Wells Fargo & Company dropped their price target on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating on the stock in a research note on Friday, February 16th. Seven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $216.19.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $152.29 on Tuesday. The firm has a market cap of $19.26 billion, a PE ratio of -56.82 and a beta of 0.41. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $218.88. The firm’s fifty day moving average is $149.35 and its two-hundred day moving average is $164.93.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.23. The business had revenue of $494.33 million during the quarter, compared to analyst estimates of $428.01 million. The company’s revenue for the quarter was up 54.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.40) earnings per share. Research analysts predict that Alnylam Pharmaceuticals will post -4.43 earnings per share for the current year.

Institutional Trading of Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Allspring Global Investments Holdings LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 143 shares in the last quarter. Quent Capital LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 246.0% in the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 123 shares in the last quarter. Anchor Investment Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $38,000. Robeco Institutional Asset Management B.V. lifted its holdings in shares of Alnylam Pharmaceuticals by 155.7% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 12,513 shares in the last quarter. Finally, GAMMA Investing LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $52,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.